Evidence map›Paper›PMID 40921865›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Predictive capacity of fracture risk assessment tools: overview of systematic reviews.

Griselda-Adriana Cruz-Priego, Berenice Araiza-Nava, Lucía Méndez-Sánchez, Delfino Vargas-Chanes, Patricia Clark

Abstract readReview
PubMed Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Forearm BMD predicts fracture independently of FRAX.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Pooled it
  2. Article
  3. Anabolic-first therapy and planned sequential care in very-high-risk fracture patients: leveraging the REFRA FLS-SEIOMM signal for global implementation.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Griselda-Adriana Cruz-PriegoClinical Epidemiology Research Unit, Hospital Infantil de Mexico "Federico Gomez", Mexico City, Mexico.ORCID http://orcid.org/0009-0002-9467-4702
Berenice Araiza-NavaClinical Epidemiology Research Unit, Hospital Infantil de Mexico "Federico Gomez", Mexico City, Mexico.
Lucía Méndez-SánchezClinical Epidemiology Research Unit, Hospital Infantil de Mexico "Federico Gomez", Mexico City, Mexico.
Delfino Vargas-ChanesUniversity Development Studies Program, National Autonomous University of Mexico, Mexico City, Mexico.
Patricia ClarkClinical Epidemiology Research Unit, Hospital Infantil de Mexico "Federico Gomez", Mexico City, Mexico. clark@unam.mx.ORCID http://orcid.org/0000-0001-7981-5357

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConduct an overview of systematic reviews of the current fracture risk prediction tools in use. MATERIAL AND

methodsWe included systematic reviews (SRs) that assessed the predictive ability of any tool, score, algorithm, or other instrument for fracture risk. The primary outcome measure was the area under the curve (AUC) representing predicted fracture risk within a specified timeframe obtained from receiver operating characteristic (ROC) analysis. We included SRs that studied both men and women with fractures in the general adult population.

resultsThe review identified 26 different tools currently in use to predict fracture risk. Within these tools a total, 21,717 different prediction variables were found. Among the different tools, a different number of factors were used ranging from the BWC model that used a single predictor variable to the GSOS tool that incorporated 21,717 predictor variables in its model (including many individual SNPs). Regarding the performance of the tools, AUC ranging from 0.58 to 0.90. None of the models had a prediction capacity greater than 90%. Most of the models are within the range of 0.7 and 0.75, but it cannot be said that any specific one stands out over the others. Rather, a fluctuating behavior is observed in all models within the different studies. The discrimination of the two most frequently validated models, including FRAX with and without BMD, varied among the studies with AUC/C index ranging from 0.58 to 0.90, respectively. Other commonly validated model, including the Garvan Model showed AUC between 0.57 to 0.84.

conclusionsThe vast majority of the models performance is within the range of 0.7 and 0.75. To compare the performance of different tools when predicting fracture, it is very important to consider the differences between prediction tools, the number of risk factors considered, as well as the nature of the variables as they will have an important impact on the feasibility of its use in clinical practice. Likewise, differences in the prediction results may depend on sex, age, types of fractures, as well as the temporal intervals of the prediction and could affect the use of the tools in the daily clinical routine.

Indexed as

Osteoporotic FracturesFemaleHumansRisk AssessmentSystematic Reviews as TopicBone mineral densityFracture risk assessment toolsOsteoporosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.